• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Commentary

Video

Adewole Adamson, MD, MPP: Getting Ready to Tackle Dermatology's Key Challenges Issues at AAD 2025

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

Adewole (Ade) Adamson, MD, MPP, FAAD, assistant professor in the Department of Dermatology at Dell Medical School, University of Texas at Austin, is preparing for this week's 2025 American Academy of Dermatology (AAD) Annual Meeting, which will take place from March 7-11 in Orlando, Florida.

At the meeting, Adamson will be participating in 2 sessions: "Approach to Melanoma Diagnosis" and "The 2025 Debates: Controversies in Dermatology," both of which will take place on Friday, March 7. These sessions promise to tackle pressing issues in dermatology, with an emphasis on melanoma diagnosis and the ongoing challenges in the specialty.

In previewing the event, Adamson shared key insights on the areas of focus for this year's meeting, specifically regarding the importance of tackling controversies within dermatology.

Adamson, who directs the Melanoma and Pigmented Lesion Clinic at Dell Seton Medical Center, works closely with patients at high risk for melanoma. He expressed that "areas of controversy are where we can learn the most and push the field the most." This perspective will drive his participation in discussions centered on advancing the field through rigorous dialogue.

As he emphasized, the AAD provides a platform for "vigorous discussions around things that matter to us all and matter to our patients."

These discussions will cover key topics such as improving diagnostic techniques and treatment approaches for melanoma, particularly for high-risk patients. Adamson’s clinical focus on melanoma management, combined with his research into pigmented lesions, will be central to his contributions at the meeting.

"The AAD is a chance to engage with colleagues and really push forward our understanding of critical dermatologic issues," Adamson said. "By addressing areas of controversy, we can challenge ourselves and ultimately improve patient outcomes."

Related Videos
© 2025 MJH Life Sciences

All rights reserved.